Journal article icon

Journal article

The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials.

Abstract:

P25 is a major surface protein of Plasmodium ookinetes. Antibodies against P25 prevent the formation of oocysts in the mosquito and thereby block transmission of the parasite through an endemic population. Plasmodium vivax transmission-blocking vaccines based on Pv25 have undergone human trials and inhibit transmission significantly. The current assay to determine transmission-blocking activity (TBA) of these sera, the 'standard membrane feeding assay', is complex and can be performed by few ...

Expand abstract

Actions


Access Document


Authors


Ramjanee, S More by this author
Robertson, JS More by this author
Franke-Fayard, B More by this author
Waters, AP More by this author
Expand authors...
Journal:
Vaccine
Volume:
25
Issue:
5
Pages:
886-894
Publication date:
2007-01-05
DOI:
EISSN:
1873-2518
ISSN:
0264-410X
URN:
uuid:90c0085f-3ef6-4b4d-93f4-6da6ba1c7efe
Source identifiers:
259075
Local pid:
pubs:259075

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP